Mesoblast Ltd (MESO) stock
MESONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30Also trades as MEOBF
$13.27+0.17 (+1.30%)
Close on Nov 13, 2026Market cap $1.72BP/E –Yield –
Mesoblast profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Mesoblast's profit margin for the twelve months ending Jun 30, 2023 was -1091.7%. For fiscal 2026 it was -47.8%, against -593.9% the year before. The highest annual figure on record is -9.7% in fiscal 2016.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | -47.8% | +546.1 |
| FY2025 | Jun 30, 2025 | -593.9% | +896.4 |
| FY2024 | Jun 30, 2024 | -1490.3% | −398.6 |
| FY2023 | Jun 30, 2023 | -1091.7% | −197.1 |
| FY2022 | Jun 30, 2022 | -894.6% | +434.6 |
| FY2021 | Jun 30, 2021 | -1329.2% | −1086.8 |
| FY2020 | Jun 30, 2020 | -242.4% | +294.6 |
| FY2019 | Jun 30, 2019 | -537.0% | −333.5 |
| FY2018 | Jun 30, 2018 | -203.5% | +2981.2 |
| FY2017 | Jun 30, 2017 | -3184.7% | −3175.0 |
| FY2016 | Jun 30, 2016 | -9.7% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | -1024.7% | −60.0 |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | -959.3% | +100.0 |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | -1147.4% | −58.7 |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | -1123.4% | −493.3 |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | -964.7% | +153.4 |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | -1059.3% | +325.3 |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | -1088.8% | +57.7 |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | -630.1% | +1250.7 |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | -1118.1% | +3533.8 |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | -1384.6% | −1259.5 |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | -1146.5% | −32.0 |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | -1880.8% | −1848.6 |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | -4651.9% | −3598.2 |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | -125.1% | +1874.1 |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | -1114.4% | +201.3 |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | -32.2% | +135.4 |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | -1053.7% | +171.8 |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | -1999.2% | −23.8 |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | -1315.7% | −1418.0 |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | -167.6% | – |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | -1225.5% | – |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | -1975.4% | – |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | 102.3% | – |
See a number that looks wrong?